Key Insights

Highlights

Success Rate

91% trial completion (above average)

Published Results

21 trials with published results (22%)

Research Maturity

62 completed trials (66% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

6.4%

6 terminated out of 94 trials

Success Rate

91.2%

+4.7% vs benchmark

Late-Stage Pipeline

28%

26 trials in Phase 3/4

Results Transparency

34%

21 of 62 completed with results

Key Signals

21 with results91% success

Data Visualizations

Phase Distribution

63Total
Not Applicable (6)
P 1 (19)
P 2 (12)
P 3 (14)
P 4 (12)

Trial Status

Completed62
Unknown13
Terminated6
Not Yet Recruiting5
Recruiting5
Enrolling By Invitation1

Trial Success Rate

91.2%

Benchmark: 86.5%

Based on 62 completed trials

Clinical Trials (94)

Showing 20 of 20 trials
NCT02154178Not ApplicableCompletedPrimary

Fungal Biomarkers to Reduce Duration of Empirical Antifungal Therapy: a Randomized Comparative Study (STAFE)

NCT06510699Phase 2RecruitingPrimary

Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial

NCT04368559Phase 3Completed

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

NCT05202366CompletedPrimary

An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection

NCT07454122Phase 1Not Yet RecruitingPrimary

CD5CAR-NK Cells for Refractory Invasive Mold Disease

NCT07238114Active Not Recruiting

Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors

NCT04818853Completed

COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)

NCT07143409Not Yet RecruitingPrimary

Fungal Vascular Graft Infections, French Multicenter Retrospective Study

NCT03828773Not ApplicableRecruiting

PTX3-targeted Antifungal Prophylaxis

NCT06774144Phase 3Enrolling By Invitation

Rezafungin Prophylaxis in Liver Transplant

NCT02956499Phase 1CompletedPrimary

Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

NCT02957929Phase 1CompletedPrimary

Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally

NCT07080359Not Yet RecruitingPrimary

Isavuconazole in Critically Ill Patients: Efficacy and Safety

NCT03717623Phase 4Recruiting

Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants

NCT05814432Phase 3Recruiting

Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS

NCT03318159Phase 2Completed

Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients

NCT05152875Completed

Relationship Between Fungal Colonization and Severe Bronchopulmonary Dysplasia

NCT01503515Phase 3CompletedPrimary

Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant

NCT05235711CompletedPrimary

The Role of Interferon-gamma in Immune Responses to Invasive Candidiasis

NCT05150327CompletedPrimary

Multicenter Cohort Study of Invasive Fungal Filamentous Fungal Infections in Liver Transplant Patients

Scroll to load more

Research Network

Activity Timeline